Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 9.02M shares outstanding
DKEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections.
The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers.
Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases.
The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Helen Katrina Tayton-Martin
Chief Executive Officer
Birgitte Rono
Chief Scientific Officer & COO
Thomas Frederik Schmidt
Chief Financial Officer
Andreas Holm Mattsson
Founder & Chief AI Officer
Employees
46
Country
DK
Sector
Healthcare
Website
evaxion-biotech.com
Loading congressional disclosures…
based on 9.02M shares outstanding
DK30d Avg
38.08K
60d Avg
305.14K
90d Avg
203.49K
